Anti-CD38 Antibody Treating Pediatric Primary Immune Thrombocytopenia (ITP)
A legfontosabb adatok
- Ki végzi
- Institute of Hematology & Blood Diseases Hospital, China
- Hol
- Tianjin (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- 2. fázis
- Résztvevők
- 60 fő, tervezett
- Kezdés
- 2023. dec. 28.
- Várható befejezés
- 2030. dec.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- Anti-CD38 antibody Injection
- A regiszteradat frissítve
- 2025. november 28.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for children and teens with primary immune thrombocytopenia (ITP, low platelets caused by the immune system). Their ITP did not respond or came back after earlier treatments.
- Életkor
- 6 to 17 years
- Nem
- All sexes
- A betegség stádiuma
- ITP diagnosed at least 3 months ago. Platelet count below 30 X 10^9/L within 2 days before joining. Daily activity score (ECOG) of 2 or less. Heart function class 2 or less.
- Korábbi kezelés
- ITP did not respond or came back after corticosteroids and at least one second-line therapy, including rituximab or TPO-RAs. Emergency ITP treatment must have ended at least 2 weeks before the first dose. Maintenance doses must be stable for at least 4 weeks. Azathioprine, danazol, cyclosporin A, tacrolimus, sirolimus must be stopped at least 4 weeks before. Rituximab ended more than 3 months ago. Spleen removal more than 6 months ago.
- Biomarker vagy leletérték
- Normal liver and kidney function.
A részvétel fő kizáró okai
- Allergy to daratumumab, or earlier daratumumab that did not work or worked for less than 6 months
- HIV positive, or uncontrolled active infection such as hepatitis B or C
- Severe bleeding, blood clot disease, or serious heart disease
- Past stem cell or organ transplant
- Pregnant or breastfeeding, or taking antiplatelet drugs
A regiszter feltételei, szó szerint
Mind a 24 feltétel megnézéseKevesebb
Ki vehet részt
- Age 6 years and above, male or female
- Conform to the diagnostic criteria of immune Thrombocytopenia (ITP)
- Diagnosis of ITP ≥3 months, and with a platelet count of <30 X 10\^9/L measured within 2 days prior to inclusion
- Failure to achieve response or relapse after corticosteroid therapy, and at least one second-line therapy including rituximab or TPORAs
- The previous emergency treatment of ITP (e.g. methylprednisolone, platelet transfusion, IVIG transfusion) must be completed at least 2 weeks before the first administration
- Signed and dated written informed consent
- With normal hepatic and renal functions
- ECOG physical state score ≤ 2 points
- Cardiac function of the New York Society of Cardiac Function ≤ 2
- Patients receiving maintenance treatment (including corticosteroids (less than or equal to 0.5mg/kg prednisone), TPO receptor agonists, etc.) must have a stable dose at least 4 weeks before the first administration, and azathioprine, danazol, cyclosporin A, tacrolimus, sirolimus, etc. must be stopped at least 4 weeks before the first administration; The end of rituximab treatment was>3 months;More than 6 months after splenectomy; March 26,2024 After approval by the Ethics Committee,age of subjects has been modified to 6 years and above upon enrollment. Approval Number: IIT2023072-EC-2
Ki nem vehet részt
- Allergy to daratumumab or its excipients, or prior treatment with daratumumab that was refractory or achieved a response lasting <6 months;
- Those who have received allogeneic stem cell transplantation or organ transplantation in the past
- Patients taking antiplatelet drugs at the same time
- Uncontrollable primary diseases of important organs, such as malignant tumors, liver failure, heart failure, renal failure and other diseases
- HIV positive
- Accompanied by uncontrollable active infection, including hepatitis B, hepatitis C, cytomegalovirus, EB virus and syphilis positive
- Accompanied by extensive and severe bleeding, such as hemoptysis, upper gastrointestinal hemorrhage, intracranial hemorrhage, etc
- At present, there are heart diseases, arrhythmias that need treatment or hypertension that researchers judge is poorly controlled
- Patients with thrombotic diseases such as pulmonary embolism, thrombosis and atherosclerosis
- Patients with mental disorders who cannot normally obtain informed consent and conduct trials and follow-up
- Other serious diseases that may limit the subject's participation in this test (such as diabetes; Severe cardiac insufficiency; Myocardial obstruction or unstable arrhythmia or unstable angina pectoris in recent 6 months; Gastric ulcer, etc.)
- Patients with septicemia or other irregular severe bleeding
- Patients whose toxic symptoms caused by pre-trial treatment have not disappeared
- Pregnant women, suspected pregnancies (positive pregnancy test for human chorionic gonadotropin in urine at screening) and lactating patients
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 6 és 17 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Kína.
- Chinese Academy of Medical Science and Blood Disease HospitalTianjin, KínaContact: Ting Sun, MDRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
To evaluate the safety and efficacy of Anti-CD38 Antibody in the treatment of pediatric primary immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line treatment and at least one second-line therapy including Anti-CD20 Antibody and/or TPO-RA, or those in whom no other second-line treatment options are suitable.
A vizsgálat csoportja
- Experimental: Intervention (Anti-CD38 antibody)A vizsgált kezelés
60 enrolled subjects : once a week x 8 doses
Kezelés: Anti-CD38 antibody Injection
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Prospective, One-arm and Open Clinical Study to Assess Safety and Efficacy of Anti-CD38 Antibody in the Treatment of Pediatric Primary Immune Thrombocytopenia
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT06168851: ki vehet részt
- A regiszteradat frissítve
- 2025. november 28.